The prognostic roles of hepatitis B virus antibody in diffuse large B-cell lymphoma patients

References

• Roschewski M, Staudt LM, Wilson WH. Diffuse large B-cell lymphoma-treatment approaches in the molecular era. Nat Rev Clin Oncol. 2014;11(1):12–23.
   PubMed Web of Science ®Google Scholar
• Grulich AE, Vajdic CM. The epidemiology of cancers in human immunodeficiency virus infection and after organ transplantation. Semin Oncol. 2015;42(2):247–257.
   PubMed Web of Science ®Google Scholar
• Goldin LR, Landgren O. Autoimmunity and lymphomagenesis. Int J Cancer. 2009;124(7):1497–1502.
   PubMed Web of Science ®Google Scholar
• Maruo S, Zhao B, Johannsen E, et al. Epstein-Barr virus nuclear antigens 3C and 3A maintain lymphoblastoid cell growth by repressing p16INK4A and p14ARF expression. Proc Natl Acad Sci USA. 2011;108(5):1919–1924.
   PubMed Web of Science ®Google Scholar
• Young LS, Rickinson AB. Epstein-Barr virus: 40 years on. Nat Rev Cancer. 2004;4(10):757–768.
   PubMed Web of Science ®Google Scholar
• Dal Maso L, Franceschi S. Hepatitis C virus and risk of lymphoma and other lymphoid neoplasms: a meta-analysis of epidemiologic studies. Cancer Epidemiol Biomarkers Prev. 2006;15(11):2078–2085.
   PubMed Web of Science ®Google Scholar
• Pinzone MR, Berretta M, Cacopardo B, et al. Epstein-barr virus- and Kaposi sarcoma-associated herpesvirus-related malignancies in the setting of human immunodeficiency virus infection. Semin Oncol. 2015;42(2):258–271.
   PubMed Web of Science ®Google Scholar
• Barton MK. Disparities found in chemotherapy administration for human immunodeficiency virus-associated lymphoma. CA Cancer J Clin. 2017;67(1):3–4.
   PubMed Web of Science ®Google Scholar
• Tarokhian H, Rahimi H, Mosavat A, et al. HTLV-1-host interactions on the development of adult T cell leukemia/lymphoma: virus and host gene expressions. BMC Cancer. 2018;18(1):1287.
   PubMed Web of Science ®Google Scholar
• Oksenhendler E, Boutboul D, Galicier L. Kaposi's sarcoma-associated herpesvirus/human herpesvirus 8 associated lymphoproliferative disorders. Blood. 2019;133(11):1186–1190.
   PubMed Web of Science ®Google Scholar
• Schweitzer A, Horn J, Mikolajczyk RT, et al. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet. 2015;386(10003):1546–1555.
   PubMed Web of Science ®Google Scholar
• Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association. The guideline of prevention and treatment for chronic hepatitis B (2010 version). Zhonghua Liu Xing Bing Xue Za Zhi. 2011;32(4):405–415.
   Google Scholar
• Liang X, Bi S, Yang W, et al. Reprint of: Epidemiological serosurvey of Hepatitis B in China–declining HBV prevalence due to Hepatitis B vaccination. Vaccine. 2013;31:J21–8.
   PubMed Web of Science ®Google Scholar
• Li X, Wang H, Li T, et al. Circulating tumor DNA/circulating tumor cells and the applicability in different causes induced hepatocellular carcinoma. Curr Probl Cancer. 2020;44(2):100516.
   PubMed Web of Science ®Google Scholar
• Engels EA, Cho ER, Jee SH. Hepatitis B virus infection and risk of non-Hodgkin lymphoma in South Korea: a cohort study. Lancet Oncol. 2010;11(9):827–834.
   PubMed Web of Science ®Google Scholar
• Li M, Gan Y, Fan C, et al. Hepatitis B virus and risk of non-Hodgkin lymphoma: an updated meta-analysis of 58 studies. J Viral Hepat. 2018;25(8):894–903.
   PubMed Web of Science ®Google Scholar
• Becker N, Schnitzler P, Boffetta P, et al. Hepatitis B virus infection and risk of lymphoma: results of a serological analysis within the European case-control study Epilymph. J Cancer Res Clin Oncol. 2012;138(12):1993–2001.
   PubMed Web of Science ®Google Scholar
• Wang L, Wu-Xiao ZJ, Chen XQ, et al. Hepatitis B virus infection correlates with poor prognosis of extranodal natural killer/T cell lymphoma. Leukemia Lymphoma. 2015;56(4):936–941.
   PubMed Web of Science ®Google Scholar
• Liu WP, Wang XP, Zheng W, et al. Hepatitis B virus reactivation after withdrawal of prophylactic antiviral therapy in patients with diffuse large B cell lymphoma. Leukemia Lymphoma. 2016;57(6):1355–1362.
   PubMed Web of Science ®Google Scholar
• Huang CE, Yang YH, Chen YY, et al. The impact of hepatitis B virus infection and vaccination on the development of non-Hodgkin lymphoma. J Viral Hepat. 2017;24(10):885–894.
   PubMed Web of Science ®Google Scholar
• Ren W, Ye X, Su H, et al. Genetic landscape of hepatitis B virus-associated diffuse large B-cell lymphoma. Blood. 2018;131(24):2670–2681.
   PubMed Web of Science ®Google Scholar
• Wang Y, Wang H, Pan S, et al. Capable infection of hepatitis B virus in diffuse large B-cell lymphoma. J Cancer. 2018;9(9):1575–1581.
   PubMed Web of Science ®Google Scholar
• Wang F, Yuan S, Teng KY, et al. High hepatitis B virus infection in B-cell lymphoma tissue and its potential clinical relevance. Eur J Cancer Prev. 2012;21(3):261–267.
   PubMed Web of Science ®Google Scholar
• Galun E, Ilan Y, Livni N, et al. Hepatitis B virus infection associated with hematopoietic tumors. Am J Pathol. 1994;145(5):1001–1007.
   PubMed Web of Science ®Google Scholar
• Cabrerizo M, Bartolome J, Caramelo C, et al. Molecular analysis of hepatitis B virus DNA in serum and peripheral blood mononuclear cells from hepatitis B surface antigen-negative cases. Hepatology. 2000;32(1):116–123.
   PubMed Web of Science ®Google Scholar
• Li M, Shen Y, Chen Y, et al. Characterization of hepatitis B virus infection and viral DNA integration in non-Hodgkin lymphoma. Int J Cancer. 2020;147(8):2199–2209.
   PubMed Web of Science ®Google Scholar
• Ziepert M, Hasenclever D, Kuhnt E, et al. Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era. J Clin Oncol. 2010;28(14):2373–2380.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999;17(4):1244.
   PubMed Web of Science ®Google Scholar
• Liang X, Bi S, Yang W, et al. Epidemiological serosurvey of hepatitis B in China–declining HBV prevalence due to hepatitis B vaccination. Vaccine. 2009;27(47):6550–6557.
   PubMed Web of Science ®Google Scholar
• Chen KL, Chen J, Rao HL, et al. Hepatitis B virus reactivation and hepatitis in diffuse large B-cell lymphoma patients with resolved hepatitis B receiving rituximab-containing chemotherapy: risk factors and survival. Chin J Cancer. 2015;34(5):225–234.
   PubMedGoogle Scholar
• Savage KJ, Slack GW, Mottok A, et al. Impact of dual expression of MYC and BCL2 by immunohistochemistry on the risk of CNS relapse in DLBCL. Blood. 2016;127(18):2182–2188.
   PubMed Web of Science ®Google Scholar
• Liu Z, Li S, Guo W, et al. MYC gene rearrangements are closely associated with poor survival of diffuse large B cell lymphoma with Hepatitis B virus infection. Biomed Res Int. 2017;2017:1967648.
   PubMed Web of Science ®Google Scholar
• Li X, Huang H, Xu B, et al. Dose-dense rituximab-CHOP versus standard rituximab-CHOP in newly diagnosed chinese patients with diffuse large B-cell lymphoma: a randomized, multicenter, open-label phase 3 trial. Cancer Res Treat. 2019;51(3):919–932.
   PubMed Web of Science ®Google Scholar
• Wang F, Xu RH, Luo HY, et al. Clinical and prognostic analysis of hepatitis B virus infection in diffuse large B-cell lymphoma. BMC Cancer. 2008;8(1):115.
   PubMed Web of Science ®Google Scholar
• Evens AM, Jovanovic BD, Su YC, et al. Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reports. Ann Oncol. 2011;22(5):1170–1180.
   PubMed Web of Science ®Google Scholar
• Pei SN, Chen CH, Lee CM, et al. Reactivation of hepatitis B virus following rituximab-based regimens: a serious complication in both HBsAg-positive and HBsAg-negative patients. Ann Hematol. 2010;89(3):255–262.
   PubMed Web of Science ®Google Scholar